Published in Ann Oncol on January 01, 1994
Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A (2009) 2.04
Spontaneous migration of cancer cells under conditions of mechanical confinement. Integr Biol (Camb) (2009) 1.81
Natural products for cancer chemotherapy. Microb Biotechnol (2010) 1.45
Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev (2008) 1.43
Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res (2011) 1.37
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer (2007) 1.22
Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol (2001) 1.21
Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med (2009) 1.13
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
The diversity of anti-microbial secondary metabolites produced by fungal endophytes: an interdisciplinary perspective. Front Microbiol (2013) 1.11
TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther (2013) 1.11
Cancer wars: natural products strike back. Front Chem (2014) 1.11
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia (2008) 1.08
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res (2010) 1.03
Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One (2013) 1.03
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med (2011) 0.96
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. Br J Cancer (2005) 0.95
The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Res (2015) 0.95
Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer. Mol Pharm (2014) 0.94
Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther (2014) 0.93
Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases. World J Surg Oncol (2007) 0.93
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst (2011) 0.92
Modulation of microtubule assembly by the HIV-1 Tat protein is strongly dependent on zinc binding to Tat. Retrovirology (2008) 0.90
Integrin imaging to evaluate treatment response. Theranostics (2011) 0.89
Estimation of the diffusion-limited rate of microtubule assembly. Biophys J (1997) 0.89
Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau. Mol Cell Biol (2006) 0.88
Biodiversity of genes encoding anti-microbial traits within plant associated microbes. Front Plant Sci (2015) 0.86
A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens. Int J Nanomedicine (2011) 0.84
Impact of vitrification on the meiotic spindle and components of the microtubule-organizing center in mouse mature oocytes. Biol Reprod (2013) 0.83
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther (2014) 0.82
Cloning and characterization of the glycoside hydrolases that remove xylosyl groups from 7-β-xylosyl-10-deacetyltaxol and its analogues. Mol Cell Proteomics (2013) 0.82
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer (2007) 0.81
Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy. Oncol Lett (2015) 0.81
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer (1998) 0.80
The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. J Transl Med (2014) 0.80
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases. Cancer Res (2016) 0.79
Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity. AAPS J (2014) 0.79
Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm (2015) 0.79
Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer. Theranostics (2016) 0.78
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford) (2011) 0.78
Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res (2013) 0.78
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. Br J Cancer (2003) 0.77
Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol (2015) 0.77
Induction of neural differentiation in rat C6 glioma cells with taxol. Brain Behav (2015) 0.77
Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics. Int J Breast Cancer (2014) 0.77
3D Chemical Similarity Networks for Structure-Based Target Prediction and Scaffold Hopping. ACS Chem Biol (2016) 0.77
Arenobufagin intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway. Oncotarget (2015) 0.76
Promotion of mitotic catastrophe via activation of PTEN by paclitaxel with supplement of mulberry water extract in bladder cancer cells. Sci Rep (2016) 0.76
Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. Mol Cell (2016) 0.76
Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res (2016) 0.76
An In Vitro Demonstration of Overcoming Drug Resistance in SKOV3 TR and MCF7 ADR with Targeted Delivery of Polymer Pro-Drug Conjugates. J Drug Target (2016) 0.75
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. Urol Clin North Am (2012) 0.75
Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Med (2014) 0.75
Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry. Toxicol Sci (2016) 0.75
Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents. Mol Imaging (2011) 0.75
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget (2016) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1 + paclitaxel for 36 mo after diagnosis. World J Gastroenterol (2007) 0.75
The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases. Int J Mol Sci (2017) 0.75
Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells. Oncol Lett (2016) 0.75
PKD3 deficiency causes alterations in microtubule dynamics during the cell cycle. Cell Cycle (2016) 0.75
Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. Small (2016) 0.75
Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy. Theranostics (2016) 0.75
Retracted The p53 breast cancer tissue biomarker in Indian women. Breast Cancer (Dove Med Press) (2011) 0.75
Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells. Oncogenesis (2017) 0.75
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. Br J Cancer (2017) 0.75
Inhibitors of plant hormone transport. Protoplasma (2015) 0.75